Clinical trial · Interventional
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.
NCT00892502CI-TRIAL-00012041Bismuth-PBHcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Blood Diseases | — | UNRESOLVED | — |
| Hematological Diseases | — | UNRESOLVED | — |
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Malignant Lymphoma | Lymphoma | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bismuth tablets | Drug | — | UNRESOLVED |
| Placebo tablets | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Bismuth tablets
- interventionNames
- Drug: Bismuth tablets
- type
- PLACEBO_COMPARATOR
- label
- 2
- description
- Placebo tablets, containing no active substance
- interventionNames
- Drug: Placebo tablets
Primary outcomes (1)
- measure
- To evaluate a possible protective effect of bismuth on the mucous membranes during chemotherapy and radiotherapy
- timeFrame
- daily during treatment
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of 18 years or over referred to the Department of Haematology L, Herlev Hospital, with a view to 'cytostatic'? treatment of or radiotherapy for haematological malignancy Exclusion Criteria: * Pregnant women and nursing mothers * No informed consent from patient * Known hyper sensitivity to bismuth or other tablet content * Severe renal insufficiency with creatinin clearance below 25 ml/min. * Patients receiving other treatment for protection of the mucous membrane except cryo treatment of the oral cavity (lumps of ice in the mouth) * Other experimental treatment within past four weeks.
References
Publications (0)
Data not yet available
No reference posted for this study.